Acylglycerol Kinase Inhibition Restores Mitophagy and Alleviates Alzheimer's Disease Pathology

Abstract

Mitophagy is a conserved cellular process that removes dysfunctional or excess mitochondria. Increasing evidence suggests that impaired mitophagy plays a crucial role in AD development. Promoting mitophagy has been shown to be protective in models of AD, representing an important target of Alzheimer's disease (AD). However, the molecular mechanisms underlying impaired mitophagy in AD are still elusive. Here, we provide evidence that highly expressed acylglycerol kinase (AGK), a mitochondrial lipid kinase associated with mitochondrial protein transport, glycolysis, and platelet formation, is a key mediator of mitophagy in AD. We found that AGK promoted the binding of ATPase family AAA domain containing 3A to translocase of the inner mitochondrial membrane 23 and sequentially increased mitochondrial import of PTEN-induced putative kinase 1, leading to the decrease of mitophagy. Further investigations revealed that the AGK downregulation in neuronal cells and APP/PS1 mice enhanced mitophagy, increased mitochondrial membrane potential, decreased pathological Tau/Aβ and neuroinflammation, and alleviated cognitive dysfunctions in the mice. Altogether our findings indicate that AGK plays a critical role in mediating mitophagy defects in AD; furthermore, downregulation of AGK promotes mitophagy and the decrease of Aβ and pathological Tau, providing an encouraging therapeutic treatment for AD.

Keywords

Alzheimer's disease / acylglycerol kinase / ATPase family AAA domain containing 3A / mitophagy / translocase of the inner mitochondrial membrane 23

References

[1] L. Ruan, X. Zhang, and R. Li, “Recent Insights Into the Cellular and Molecular Determinants of Aging,” Journal of Cell Science 131, no. 3 (2018): jcs210831.

[2] K. Zeng, X. Yu, Y. A. R. Mahaman, et al., “Defective Mitophagy and the Etiopathogenesis of Alzheimer's Disease,” Transl Neurodegener 11, no. 1 (2022): 32.

[3] P. I. Moreira, C. Carvalho, X. Zhu, M. A. Smith, and G. Perry, “Mitochondrial Dysfunction Is a Trigger of Alzheimer's Disease Pathophysiology,” Biochimica Et Biophysica Acta 1802, no. 1 (2010): 2–10.

[4] K. Palikaras, I. Daskalaki, M. Markaki, and N. Tavernarakis, “Mitophagy and Age-related Pathologies: Development of New Therapeutics by Targeting Mitochondrial Turnover,” Pharmacology & Therapeutics 178 (2017): 157–174.

[5] R. W. Button, S. Luo, and D. C. Rubinsztein, “Autophagic Activity in Neuronal Cell Death,” Neurosci Bull 31, no. 4 (2015): 382–394.

[6] D. C. David, S. Hauptmann, I. Scherping, et al., “Proteomic and Functional Analyses Reveal a Mitochondrial Dysfunction in P301L Tau Transgenic Mice,” Journal of Biological Chemistry 280, no. 25 (2005): 23802–23814.

[7] L. Esposito, J. Raber, L. Kekonius, et al., “Reduction in Mitochondrial Superoxide Dismutase Modulates Alzheimer's Disease-Like Pathology and Accelerates the Onset of Behavioral Changes in human Amyloid Precursor Protein Transgenic Mice,” Journal of Neuroscience 26, no. 19 (2006): 5167–5179.

[8] R. H. Swerdlow, “Mitochondria and Mitochondrial Cascades in Alzheimer's Disease,” Journal of Alzheimer's Disease 62, no. 3 (2018): 1403–1416.

[9] P. Tammineni, X. Ye, T. Feng, D. Aikal, and Q. Cai, “Impaired Retrograde Transport of Axonal Autophagosomes Contributes to Autophagic Stress in Alzheimer's disease Neurons,” Elife 6 (2017): e21776.

[10] X. Cen, Y. Chen, X. Xu, et al., “Pharmacological Targeting of MCL-1 Promotes Mitophagy and Improves Disease Pathologies in an Alzheimer's Disease Mouse Model,” Nature Communications 11, no. 1 (2020): 5731.

[11] J. A. Pradeepkiran and P. H. Reddy, “Defective Mitophagy in Alzheimer's Disease,” Ageing Research Reviews 64 (2020): 101191.

[12] E. F. Fang, Y. Hou, K. Palikaras, et al., “Mitophagy Inhibits Amyloid-β and Tau Pathology and Reverses Cognitive Deficits in Models of Alzheimer's Disease,” Nature Neuroscience 22, no. 3 (2019): 401–412.

[13] G.-L. McLelland, S. A. Lee, H. M. McBride, and E. A. Fon, “Syntaxin-17 Delivers PINK1/Parkin-dependent Mitochondrial Vesicles to the Endolysosomal System,” Journal of Cell Biology 214, no. 3 (2016): 275–291.

[14] C. Figueiredo-Pereira, B. Villarejo-Zori, P. C. Cipriano, et al., “Carbon Monoxide Stimulates both Mitophagy and Mitochondrial Biogenesis to Mediate Protection against Oxidative Stress in Astrocytes,” Molecular Neurobiology 60, no. 2 (2023): 851–863.

[15] J. Nunnari and A. Suomalainen, “Mitochondria: In Sickness and in Health,” Cell 148, no. 6 (2012): 1145–1159.

[16] A. Khaminets, C. Behl, and I. Dikic, “Ubiquitin-Dependent and Independent Signals in Selective Autophagy,” Trends in Cell Biology 26, no. 1 (2016): 6–16.

[17] A. M. Pickrell and R. J. Youle, “The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson's Disease,” Neuron 85, no. 2 (2015): 257–273.

[18] N. Wiedemann and N. Pfanner, “Mitochondrial Machineries for Protein Import and Assembly,” Annual Review of Biochemistry 86 (2017): 685–714.

[19] K. Okatsu, M. Uno, F. Koyano, et al., “A Dimeric PINK1-containing Complex on Depolarized Mitochondria Stimulates Parkin Recruitment,” Journal of Biological Chemistry 288, no. 51 (2013): 36372–36384.

[20] K. Tanaka, “The PINK1-Parkin Axis: An Overview,” Neuroscience Research 159 (2020): 9–15.

[21] A. Ordureau, J. A. Paulo, W. Zhang, et al., “Dynamics of PARKIN-Dependent Mitochondrial Ubiquitylation in Induced Neurons and Model Systems Revealed by Digital Snapshot Proteomics,” Molecular Cell 70, no. 2 (2018): 211–227.

[22] G. Jin, C. Xu, X. Zhang, et al., “Atad3a suppresses Pink1-dependent Mitophagy to Maintain Homeostasis of Hematopoietic Progenitor Cells,” Nature Immunology 19, no. 1 (2018): 29–40.

[23] M. Di Rienzo, A. Romagnoli, F. Ciccosanti, et al., “AMBRA1 regulates Mitophagy by Interacting With ATAD3A and Promoting PINK1 Stability,” Autophagy 18, no. 8 (2022): 1752–1762.

[24] B. Chu, Z. Hong, and X. Zheng, “Acylglycerol Kinase-Targeted Therapies in Oncology,” Frontiers in Cell and Developmental Biology 9 (2021): 659158.

[25] D. P. Narendra, S. M. Jin, A. Tanaka, et al., “PINK1 is Selectively Stabilized on Impaired Mitochondria to Activate Parkin,” Plos Biology 8, no. 1 (2010): e1000298.

[26] N. Matsuda, S. Sato, K. Shiba, et al., “PINK1 stabilized by Mitochondrial Depolarization Recruits Parkin to Damaged Mitochondria and Activates Latent Parkin for Mitophagy,” Journal of Cell Biology 189, no. 2 (2010): 211–221.

[27] D. Narendra, A. Tanaka, D.-F. Suen, and R. J. Youle, “Parkin Is Recruited Selectively to Impaired Mitochondria and Promotes Their Autophagy,” Journal of Cell Biology 183, no. 5 (2008): 795–803.

[28] J. Hu, T. Liu, F. Fu, et al., “Omentin1 ameliorates Myocardial Ischemia-induced Heart Failure via SIRT3/FOXO3a-dependent Mitochondrial Dynamical Homeostasis and Mitophagy,” Journal of translational medicine 20, no. 1 (2022): 447.

[29] Z. Deng, H. Ou, F. Ren, et al., “LncRNA SNHG14 Promotes OGD/R-induced Neuron Injury by Inducing Excessive Mitophagy via miR-182-5p/BINP3 Axis in HT22 Mouse Hippocampal Neuronal Cells,” Biological Research 53, no. 1 (2020): 38.

[30] X. Wu, Y. Zheng, M. Liu, et al., “BNIP3L/NIX Degradation Leads to Mitophagy Deficiency in Ischemic Brains,” Autophagy 17, no. 8 (2021): 1934–1946.

[31] T. Arguello, S. Peralta, H. Antonicka, et al., “ATAD3A has a Scaffolding Role Regulating Mitochondria Inner Membrane Structure and Protein Assembly,” Cell reports 37, no. 12 (2021): 110139.

[32] K. Palikaras, E. Lionaki, and N. Tavernarakis, “Mechanisms of Mitophagy in Cellular Homeostasis, Physiology and Pathology,” Nature Cell Biology 20, no. 9 (2018): 1013–1022.

[33] P. H. Reddy, R. Tripathi, Q. Troung, et al., “Abnormal Mitochondrial Dynamics and Synaptic Degeneration as Early Events in Alzheimer's Disease: Implications to Mitochondria-targeted Antioxidant Therapeutics,” Biochimica Et Biophysica Acta 1822, no. 5 (2012): 639–649.

[34] R. X. Santos, S. C. Correia, X. Wang, et al., “A Synergistic Dysfunction of Mitochondrial Fission/Fusion Dynamics and Mitophagy in Alzheimer's Disease,” Journal of Alzheimer's Disease 20 (2010): S401–S412, Suppl 2(Suppl 2).

[35] R. H. Swerdlow and S. M. Khan, “A “Mitochondrial Cascade Hypothesis” for Sporadic Alzheimer's Disease,” Medical Hypotheses 63, no. 1 (2004): 8–20.

[36] R. H. Swerdlow, J. M. Burns, and S. M. Khan, “The Alzheimer's Disease Mitochondrial Cascade Hypothesis: Progress and Perspectives,” Biochimica Et Biophysica Acta 1842, no. 8 (2014): 1219–1231.

[37] O. Schmidt, N. Pfanner, and C. Meisinger, “Mitochondrial Protein Import: From Proteomics to Functional Mechanisms,” Nature Reviews Molecular Cell Biology 11, no. 9 (2010): 655–667.

[38] M. Lazarou, S. M. Jin, L. A. Kane, and R. J. Youle, “Role of PINK1 Binding to the TOM Complex and Alternate Intracellular Membranes in Recruitment and Activation of the E3 Ligase Parkin,” Developmental Cell 22, no. 2 (2012): 320–333.

[39] S. Dolci, L. Mannino, E. Bottani, et al., “Therapeutic Induction of Energy Metabolism Reduces Neural Tissue Damage and Increases Microglia Activation in Severe Spinal Cord Injury,” Pharmacological Research 178 (2022): 106149.

[40] F. Yin, H. Sancheti, I. Patil, and E. Cadenas, “Energy Metabolism and Inflammation in Brain Aging and Alzheimer's Disease,” Free Radic Biol Med 100 (2016): 108–122.

[41] C.-O. Davis, K.-Y. Kim, E. A. Bushong, et al., “Transcellular Degradation of Axonal Mitochondria,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 26 (2014): 9633–9638.

[42] K. Hayakawa, E. Esposito, X. Wang, et al., “Transfer of Mitochondria From Astrocytes to Neurons After Stroke,” Nature 535, no. 7613 (2016): 551–555.

[43] L. Holcomb, M. N. Gordon, E. McGowan, et al., “Accelerated Alzheimer-type Phenotype in Transgenic Mice Carrying both Mutant Amyloid Precursor Protein and Presenilin 1 Transgenes,” Nature Medicine 4, no. 1 (1998): 97–100.

[44] S. Oddo, A. Caccamo, J. D. Shepherd, et al., “Triple-transgenic Model of Alzheimer's Disease With Plaques and Tangles: Intracellular Abeta and Synaptic Dysfunction,” Neuron 39, no. 3 (2003): 409–421.

[45] P. Langfelder and S. Horvath, “WGCNA: An R Package for Weighted Correlation Network Analysis,” BMC Bioinformatics 9 (2008): 559.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.